Nanoform Finland Oyj

Equities

NANOFH

FI4000330972

Biotechnology & Medical Research

Delayed Nasdaq Helsinki 04:24:25 2024-04-23 am EDT 5-day change 1st Jan Change
2.66 EUR -0.56% Intraday chart for Nanoform Finland Oyj +4.93% +67.82%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Nanoform Finland to Deliver Nanomedicine Technology to Japan MT
Nanoform Enters Exclusive Partnership with CBC to Bring Best-In-Class Nanomedicine Technology to Japan CI
Nanoform Teams Up with PlusVitech to Repurpose Anti-Nausea Drug for Lung Cancer Treatment MT
Nanoform Finland plc and Plusvitech Partner to Repurpose Aprepitant as A Treatment for Lung Cancer CI
Nanoform Finland Oyj Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Nanoform Finland Oyj Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Transcript : Nanoform Finland Oyj, 2023 Earnings Call, Feb 29, 2024
Nanoform Finland plc Receives Positive Results from its Own Pre- Clinical, In-Vivo Study of a Nanocrystalline-Enabled Apalutamide Oral Formulation CI
Transcript : Nanoform Finland Oyj - Special Call
Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide CI
Nanoform Finland Starts Clinical Trial for Nanocrystalline Alternative of Prostrate Cancer Drug MT
Nanoform Finland plc Commences Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide CI
Transcript : Nanoform Finland Oyj, Q3 2023 Earnings Call, Nov 22, 2023
Nanoform Finland Oyj Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Nanoform Finland Signs Licensing Deal for AI Technology with AstraZeneca MT
Nanoform Grant Global STARMAP[®] AI License to AstraZeneca CI
Transcript : Nanoform Finland Oyj, Q2 2023 Earnings Call, Aug 24, 2023
Nanoform Finland Oyj Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Finland’s Nanoform, Celanese to Advance Partnership in Nanoparticle-enabled Drug Delivery Study MT
Nanoform and Celanese Demonstrate Enhanced Drug Delivery Through the Power of Smaller Implants CI
Transcript : Nanoform Finland Oyj, Q1 2023 Earnings Call, May 25, 2023
Nanoform Finland Oyj Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Finnish Medicines Agency Renews Nanoform's GMP License and Nanoform Starts Clinical API Manufacturing of Blockbuster Medicine Candidate CI
Nanoform Finland plc Announces Board Appointments CI
Transcript : Nanoform Finland Oyj, Q4 2022 Earnings Call, Feb 28, 2023
Chart Nanoform Finland Oyj
More charts
Nanoform Finland Oyj is a Finland-based company that operates in the global pharmaceutical industry. The Company is an early-stage growth Company that develops various nanoforming technologies for application in the field of nanomedicine. Nanoform Finland Oyj’s business is to offer expert services in nanotechnology as well as drug particle engineering for global pharma and biotech industry. Nanoform Finland Oyj is the Parent Company of the Nanoform Group, and it has one subsidiary - Nanoform USA Inc. The Group production, research and development functions operate in Finland. The Group’s strategy is to sell nanotechnological services widely to minimize the dependence from single customers or projects.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.675 EUR
Average target price
4.4 EUR
Spread / Average Target
+64.49%
Consensus
  1. Stock Market
  2. Equities
  3. NANOFH Stock
  4. News Nanoform Finland Oyj
  5. Nanoform Finland Oyj : Upgrades Business Targets For 2025; Shares Up 8%